59 related articles for article (PubMed ID: 15775409)
1. [Suppressive effects of bisphosphonates on the vascular calcification in ESRD patients].
Tamura K; Hashiba H; Kogo H; Aizawa S; Shigematsu T
Clin Calcium; 2002 Aug; 12(8):1129-35. PubMed ID: 15775409
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients.
Hashiba H; Aizawa S; Tamura K; Shigematsu T; Kogo H
Ther Apher Dial; 2004 Jun; 8(3):241-7. PubMed ID: 15154878
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects.
Hashiba H; Aizawa S; Tamura K; Kogo H
Ther Apher Dial; 2006 Feb; 10(1):59-64. PubMed ID: 16556138
[TBL] [Abstract][Full Text] [Related]
4. Prevention of aortic calcification by etidronate in the renal failure rat model.
Tamura K; Suzuki Y; Matsushita M; Fujii H; Miyaura C; Aizawa S; Kogo H
Eur J Pharmacol; 2007 Mar; 558(1-3):159-66. PubMed ID: 17270170
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease.
Sigrist MK; Taal MW; Bungay P; McIntyre CW
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1241-8. PubMed ID: 17928470
[TBL] [Abstract][Full Text] [Related]
7. Coronary and aortic calcifications in patients new to dialysis.
Spiegel DM; Raggi P; Mehta R; Lindberg JS; Chonchol M; Ehrlich J; James G; Chertow GM; Block GA
Hemodial Int; 2004 Jul; 8(3):265-72. PubMed ID: 19379426
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
Toussaint ND; Elder GJ; Kerr PG
Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
[TBL] [Abstract][Full Text] [Related]
9. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita M; Nagashima M; Wauke K; Takahashi H; Takenouchi K
J Rheumatol; 2008 Mar; 35(3):407-13. PubMed ID: 18260178
[TBL] [Abstract][Full Text] [Related]
10. [Bone mineral density and vascular calcification].
Joki N; Hase H; Imamura Y
Clin Calcium; 2005 Jul; 15(7):131-6. PubMed ID: 15995309
[TBL] [Abstract][Full Text] [Related]
11. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
12. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
13. Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study.
Othmane Tel H; Bakonyi G; Egresits J; Fekete BC; Fodor E; Jarai Z; Jekkel C; Nemcsik J; Szabo A; Szabo T; Kiss I; Tisler A
Hemodial Int; 2007 Oct; 11 Suppl 3():S13-21. PubMed ID: 17897105
[TBL] [Abstract][Full Text] [Related]
14. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium.
Spasovski G; Gelev S; Masin-Spasovska J; Selim G; Sikole A; Vanholder R
Bone; 2007 Oct; 41(4):698-703. PubMed ID: 17643363
[TBL] [Abstract][Full Text] [Related]
15. [Pathogenesis and therapy for vascular calcification in patients on chronic hemodialysis].
Nitta K
Clin Calcium; 2005 Jul; 15(7):106-14. PubMed ID: 15995305
[TBL] [Abstract][Full Text] [Related]
16. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease.
Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
Nephrol Dial Transplant; 2008 Feb; 23(2):586-93. PubMed ID: 17933842
[TBL] [Abstract][Full Text] [Related]
17. [Control of arterial hypertension by means of a regimen of hemodialysis on alternate days (HDAA or EODD: "Every Other Day Dialysis") versus 2 conventional regiments of 4 and 5 hours per session 3 times a week with 72 hours without sessions during the weekends].
Lozano A; Benavides B; Quirós P; Jiménez-Moreno J; Figueroa E; Fernández-Marchena D; García-Pérez MA; Fernández-Ruiz E
Nefrologia; 2006; 26(6):695-702. PubMed ID: 17227247
[TBL] [Abstract][Full Text] [Related]
18. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Kikuchi Y; Imakiire T; Yamada M; Saigusa T; Hyodo T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Suzuki S; Miura S
Nephrol Dial Transplant; 2007 Jun; 22(6):1593-600. PubMed ID: 17041001
[TBL] [Abstract][Full Text] [Related]
19. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D deficiency and associated factors in hemodialysis patients.
Jean G; Charra B; Chazot C
J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
